At the end of the latest market close, Inhibikase Therapeutics Inc. (IKT) was valued at $0.91. In that particular session, Stock kicked-off at the price of $0.788 while reaching the peak value of $0.93 and lowest value recorded on the day was $0.775. The stock current value is $1.00.Recently in News on January 25, 2023, Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson’s Disease and Related Disorders. – Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of Parkinson’s Disease and Suppress Protein Pathology -. You can read further details here
Inhibikase Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.1573 on 01/25/23, with the lowest value was $0.4850 for the same time period, recorded on 01/03/23.
Inhibikase Therapeutics Inc. (IKT) full year performance was -31.06%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Inhibikase Therapeutics Inc. shares are logging -34.22% during the 52-week period from high price, and 127.20% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.44 and $1.52.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 6124580 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Inhibikase Therapeutics Inc. (IKT) recorded performance in the market was 82.00%, having the revenues showcasing 12.33% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 22.08M, as it employees total of 6 workers.
Specialists analysis on Inhibikase Therapeutics Inc. (IKT)
During the last month, 0 analysts gave the Inhibikase Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.7156, with a change in the price was noted +0.03. In a similar fashion, Inhibikase Therapeutics Inc. posted a movement of +3.17% for the period of last 100 days, recording 153,326 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for IKT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Inhibikase Therapeutics Inc. (IKT)
Raw Stochastic average of Inhibikase Therapeutics Inc. in the period of last 50 days is set at 76.35%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.35%. In the last 20 days, the company’s Stochastic %K was 87.01% and its Stochastic %D was recorded 85.71%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 82.00%. Additionally, trading for the stock in the period of the last six months notably improved by 4.11%, alongside a downfall of -31.06% for the period of the last 12 months. The shares increased approximately by 44.42% in the 7-day charts and went down by 89.58% in the period of the last 30 days. Common stock shares were driven by 12.33% during last recorded quarter.